Abstract:Testing of drug effects and cytotoxicity by using cultured cells has been widely performed as an alternative to animal testing. However, the estimation of pharmacokinetics by conventional cell-based assay methods is difficult because of the inability to evaluate multiorgan effects. An important challenge in the field is to mimic the organ-to-organ network in the human body by using a microfluidic network connecting small-scale tissues based on recently emerging MicroTAS (Micro Total Analysis Systems) technology for prediction of pharmacokinetics. Here, we describe an on-chip small intestine-liver coupled model for pharmacokinetic studies. To construct an in vitro pharmacokinetic model that appropriately models in vivo conditions, physiological parameters such as the structure of internal circulation, volume ratios of each organ, and blood flow ratio of the portal vein to the hepatic artery were mimicked using microfluidic networks. To demonstrate interactions between organs in vitro in pharmacokinetic studies, Caco-2, HepG2, and A549 cell cultures were used as organ models of the small intestine, liver, and lung, respectively, and connected to each other through a microporous membrane and microchannels to prepare a simple model of a physiological organ-to-organ network. The on-chip organ model assay using three types of substrate-epirubicine (EPI), irinotecan (CPT-11), and cyclophosphamide (CPA)-were conducted to model the effects of orally administered or biologically active anticancer drugs. The result suggested that the device can replicate physiological phenomena such as activity of the anticancer drugs on the target cells. This microfluidic device can thus be used as an in vitro organ model to predict the pharmacokinetics of drugs in the human body and may thus provide not only an alternative to animal testing but also a method of obtaining parameters for in silico models of physiologically based pharmacokinetics.

Multi-organ-on-a-chip for pharmacokinetics and toxicokinetic study of drugs

Pharmacokinetic and pharmacodynamic insights from microfluidic intestine-on-a-chip models

In situ biosensing technologies for an organ-on-a-chip

“Multi-Organ-on-a-Chip” for Drug Testing Applications

Trends in Organ-on-a-chip for Pharmacological Analysis

Engineering Organoids-on-chips for Drug Testing and Evaluation

Advances in Human Organs-on-Chips and Applications for Drug Screening and Personalized Medicine

Recent Organ-on-a-chip Advances Toward Drug Toxicity Testing

Drug Toxicity Evaluation Based on Organ-on-a-chip Technology: A Review

PBPK Modeling on Organs-on-Chips: An Overview of Recent Advancements

Organ/body-on-a-chip based on microfluidic technology for drug discovery

State-of-the-art in high throughput organ-on-chip for biotechnology and pharmaceuticals

Organ-on-a-chip: A new tool for in vitro research

An update on microfluidic multi-organ-on-a-chip systems for reproducing drug pharmacokinetics: the current state-of-the-art

An On-Chip Small Intestine–Liver Model for Pharmacokinetic Studies

Organs-on-chips at the frontiers of drug discovery

Revolutionizing drug development: harnessing the potential of organ-on-chip technology for disease modeling and drug discovery

Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips

Emerging Trends in Organ-on-a-chip Systems for Drug Screening